Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 57.76 USD 0.31%
Market Cap: 117.1B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bristol-Myers Squibb Co
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Other Long-Term Assets
$6.2B
CAGR 3-Years
38%
CAGR 5-Years
13%
CAGR 10-Years
13%
Johnson & Johnson
NYSE:JNJ
Other Long-Term Assets
$19.8B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
9%
Pfizer Inc
NYSE:PFE
Other Long-Term Assets
$18.6B
CAGR 3-Years
25%
CAGR 5-Years
27%
CAGR 10-Years
15%
Merck & Co Inc
NYSE:MRK
Other Long-Term Assets
$13.3B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Zoetis Inc
NYSE:ZTS
Other Long-Term Assets
$624m
CAGR 3-Years
41%
CAGR 5-Years
31%
CAGR 10-Years
18%
Eli Lilly and Co
NYSE:LLY
Other Long-Term Assets
$12.5B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
18%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
117.1B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
70.82 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Other Long-Term Assets?
Other Long-Term Assets
6.2B USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Other Long-Term Assets amounts to 6.2B USD.

What is Bristol-Myers Squibb Co's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
13%

Over the last year, the Other Long-Term Assets growth was 63%. The average annual Other Long-Term Assets growth rates for Bristol-Myers Squibb Co have been 38% over the past three years , 13% over the past five years , and 13% over the past ten years .

Back to Top